FGX International Launches Foster Grant Eyezen Designed For A Connected Life

New Eyezen glasses help fight the temporary effects of digital eye
strain caused by screens and tablets

SMITHFIELD, R.I.–(BUSINESS WIRE)–FGX International, a leading eyewear designer and marketer, announced
today the launch of the new Foster Grant® Eyezen™ glasses, designed for
your connected life. The non-prescription glasses from Essilor relax
your eyes and help fight the temporary effects of digital eye strain.

The Foster Grant Eyezen collection, by Essilor retails for $34.99 and is
available online at fostergranteyezen.com and Amazon.com. The
non-prescription collection features eight, contemporary styles for men
and women 18+. The glasses employ two new technologies that provide a
heightened layer of protection against digital eye strain: a patented
lens coating technology that blocks potentially Harmful Blue Light and
SmartFocus™ Technology, which provides a small amount of accommodative
relief in the lower portion of the lens to help the eyes stay relaxed
while using digital devices.

Digital eye strain causes tired, heavy-feeling eyes, difficulties
reading digital screens and general eye discomfort. According to The
Vision Council1, nearly 90% of people daily use digital
devices, with nearly 60% of Americans using digital devices five hours
or more per day.

“With people spending so much time at work and home glued to digital
devices, digital eye strain is becoming an increasingly prevalent
issue,” said Gina Lazaro, EVP Global Marketing for FGX. “Foster Grant is
excited to launch Eyezen as a response to this growing consumer need,
and the innovative technology our team has employed in these glasses
will offer customers a more pleasant digital experience.”

The Foster Grant Eyezen launch is part of a global introduction of the
Eyezen brand from Essilor, the world’s leading ophthalmic optics company.

About FGX International
FGX International is a wholly-owned
subsidiary of Essilor International. FGX International is a leading
designer and marketer of sunglasses, optical frames and non-prescription
reading glasses with a portfolio of established, highly recognized
eyewear brands including Foster Grant®, Ryders®, Magnivision®,
Gargoyles®, Corinne McCormack®, Solar Shield®, and Polinelli®. FGX
International also holds licenses for brands such as Reebok®, Revlon®,
Ironman®, Dockers®, Nine West®, and Panama Jack®. Based in Smithfield,
Rhode Island in the United States, FGX International has additional
offices located in New York City; San Luis Obispo, California; Toronto,
Canada; Vancouver, Canada; Milan, Italy; Stoke-on-Trent, England;
Chessington, England; Mexico City, Mexico; Bangalore, India and
Shenzhen, China. For more information about FGX International, please
visit the www.fgxi.com

About Essilor
The world’s leading ophthalmic optics company,
Essilor designs, manufactures and markets a wide range of lenses to
improve and protect eyesight. Its mission is to improve lives by
improving sight. To support this mission, Essilor allocates more than
€200 million to research and innovation every year, in a commitment to
continuously bring new, more effective products to market. Its flagship
brands are Varilux® , Crizal ® , Transitions® , EyezenTM, Xperio® ,
Foster Grant® , BolonTM and Costa® . It also develops and markets
equipment, instruments and services for eyecare professionals. Essilor
reported consolidated revenue of more than €6.7 billion in 2015 and
employs 61,000 people worldwide. It markets its products in more than
100 countries and has 32 plants, 490 prescription laboratories and
edging facilities, as well as 5 research and development centers around
the world. For more information, please visit essilor.com The Essilor
share trades on the Euronext Paris market and is included in the Euro
Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667;
Reuters: ESSI.PA; Bloomberg: EI:FP.

1“Eyes Over Exposed: The Digital Device Dilemma”, 2016 Digital Eye
Strain Report, The Vision Council.


For FGX International
Cait Arsenault, 401-278-4471